S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Hang Feng Technology Reports Loss Amid Strategic Pivot to RWA

Hong Kong-based Hang Feng Technology Innovation Co., Ltd. swung to a net loss of $553,033 in the first half of 2026, marking a sharp departure from the $363,524 profit recorded during the same period last year as the firm de-prioritized its traditional consulting business to pursue new RWA initiatives.

Hang Feng Technology Reports Loss Amid Strategic Pivot to RWA
Photo: Bio & News

The company’s revenue plummeted to $362,511, down from $1,327,707 in the first half of 2025. Management attributed this decline to a deliberate reduction in marketing and business development for its consulting arm, opting instead to reallocate capital toward real-world asset (RWA) development. Despite the operating losses, the firm maintains a liquid position with $6.6 million in cash and total assets valued at $8.2 million, bolstered by $329,755 in interest income from loans.

CEO Xu Zhiheng framed the performance as a necessary phase of strategic reassessment. To support its future roadmap, the company incorporated a Singapore-based subsidiary, HF Helios AI PTE Limited, in May. Meanwhile, the firm successfully completed a capital reorganization, shifting its structure to accommodate 9 billion Class A and 1 billion Class B shares. On the regulatory front, the company’s asset management unit, HF IAM, secured a Type 1 license for dealing in securities in July, adding to its existing Type 4 and Type 9 authorizations in Hong Kong.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!